The The Brazilian Ministry of Health reported this Thursday that it plans to discontinue the use of the anticovid vaccine developed by the Chinese laboratory Sinovac as of 2022, due to its “low effectiveness” in the population over 80 years of age.
In a document sent to the Senate commission that investigates the management of the Brazilian government against the coronavirus, to which local media had access, the portfolio pointed out that, in addition, the so-called Coronavac only has temporary approval by the health authorities.
“The reason for the possible discontinuation of the Coronavac vaccine in 2022 is directly related to the evaluation status by the Anvisa “(National Health Surveillance Agency, regulator), explained the wallet.
He added that the temporary authorization for emergency use was granted “to minimize, as quickly as possible, the impacts of the disease in the national territory “.
The document was sent to the parliamentary commission after it had given a period of 48 hours for the Ministry to explain the possible interruption of the use of the immunizer in the country’s vaccination campaign, which already accumulates almost 600,000 deaths and 21.5 million cases of COVID-19.
Thus, the Ministry also justified that the data obtained so far “have shown the low effectiveness of the immunizer in the population over 80 years of age “.
The Ministry also reported that it foresees the delivery of another 207.8 million vaccines until December, of which almost 100 million would correspond to Pfizer, 36.1 million to Janssen and 71.6 million from AstraZeneca.
“Considering that for the conclusion of the year 2021 we have the forecast of need of 73,707,379 doses” and the contracts signed by the Government “have a pending quantity of 207,870,340 doses, there will be a forecast of 134,192,961 remaining doses for 2022 “, he completed.
The Coronavac, from the Chinese laboratory Sinovac, but which is produced in Brazil by el Instituto Butantan de Sao Paulo, It was the first vaccine to be used in the South American country and currently accounts for 31.9% of the total doses applied so far, according to official data.
The formula of AstraZeneca/Oxford, which corresponds to 42.7% of the total, that of US-German consortium Pfizer / BioNTech (23.4%) and the Belgian Janssen, of the multinational Johnson & Johnson (2.0%), which is single-dose.
Until this Thursday, about 70% of the 213 million inhabitants of Brazil They had already received the first puncture against COVID-19, while 45.2% have the complete guideline.
Follow and listen to the Interpreter on Spotify:
–
